Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online August 28, 2018]. J Clin Oncol. 2018:Jco2018783118. doi: 10.1200/JCO.2018.78.3118.
Advertisement
Articles by Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer [published online August 28, 2018]. J Clin Oncol. 2018:Jco2018783118. doi: 10.1200/JCO.2018.78.3118.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
3
Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD
4
The Next Frontier in Hepatitis B Functional and Virologic Cure
5